Adocia SA is a pharmaceutical company committed to enhancing the lives of individuals with chronic diseases through innovative drug development. With a strong focus on developing and commercializing therapeutic solutions, Adocia SA prioritizes the well-being and satisfaction of patients. The company champions a corporate philosophy rooted in research excellence, patient-centricity, and collaboration. Adocia SA aims to revolutionize treatment options by leveraging cutting-edge technology and partnerships with industry leaders. By consistently delivering high-quality products, Adocia SA strives to make a lasting positive impact on the healthcare industry, ensuring better outcomes for patients worldwide.

Adocia SA is primarily present in France.

Adocia SA has achieved several significant milestones in its journey. One notable achievement is the successful completion of multiple clinical trials for their innovative biopharmaceutical products. Another milestone includes the development and FDA approval of various insulin formulations using their proprietary BioChaperone® technology. Furthermore, Adocia has successfully established partnerships with renowned pharmaceutical companies, expanding its global reach and enhancing its research and development capabilities. These accomplishments demonstrate Adocia SA's commitment to advancing healthcare solutions and solidify its position as a leading player in the biotech industry.

Adocia SA is a global biotechnology company founded in 2005 and based in France. The company specializes in the development of innovative formulations of proteins and peptides for the treatment of diabetes and other metabolic disorders. Adocia's history is marked by significant milestones, including successful clinical trials and collaborations with leading pharmaceutical companies. With a strong focus on research and development, Adocia has built an impressive intellectual property portfolio and expertise in formulation technology. The company's commitment to improving the lives of patients through advanced therapeutic solutions has positioned Adocia as a key player in the biopharmaceutical industry globally.

The main competitors of Adocia SA in the market include other pharmaceutical companies specializing in the development and commercialization of innovative therapies. Some notable competitors of Adocia SA include Novo Nordisk, Sanofi, Eli Lilly, and Johnson & Johnson. These companies are actively involved in the research and development of new treatments for diabetes and other related diseases, similar to Adocia SA.

Adocia SA is primarily active in the pharmaceutical industry.

Adocia SA is a biotechnology company specializing in the development of innovative therapies for diabetic patients. The company's business model revolves around the research and development of biopharmaceutical products, particularly focused on the field of diabetes and metabolic disorders. Adocia develops proprietary formulations of approved therapeutic proteins to enhance their effectiveness and improve patient convenience. By leveraging its expertise in formulation science and strategic partnerships, Adocia aims to provide safer and more efficient treatments for patients worldwide. With a focus on diabetes, Adocia SA's business model revolves around creating innovative solutions to better manage the disease and improve patients' quality of life.

Adocia P/E suhe on 1,11.

Adocia KUV on 1,00.

AlleAktien kvaliteediskoor ettevõttele Adocia on 5/10.

oodatud Adocia käive on 61,71 mln. EUR.

oodatud Adocia kasum on 55,54 mln. EUR.

Adocia SA is a French biotech company that focuses on the development of innovative insulin therapies and other biopharmaceutical preparations. The company's business model is based on researching and developing novel therapy approaches that have a wide range of applications and high efficacy. Adocia operates in three main business areas: diabetes, autoimmune diseases, and cancer. In the diabetes field, the company is working on insulin preparations that help patients with type 1 and type 2 diabetes better control their blood sugar levels. Adocia has developed a range of insulin products, including an ultrafast insulin formulation, a long-acting combination formulation, and a combination formulation with glucagon-like peptide-1 (GLP-1). Adocia is also working on the development of therapies for autoimmune diseases such as Crohn's disease and multiple sclerosis. An innovative product from Adocia is a drug combination developed based on antibodies against tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6). This drug combination has the potential to reduce inflammation in a range of autoimmune diseases. Another important area of business for Adocia is cancer therapy. The company is focused on developing drug combinations based on antibodies and other biological therapies. These drug combinations have the potential to attack cancer cells in various ways while stimulating the body's immune system. To finance the development of these therapies, Adocia has developed an innovative funding model. The company works closely with investment banks and venture capital funds to raise funds necessary for the research and development of new therapy options. Adocia is also involved in successful public offerings and has the opportunity to raise further funding options through issuing shares. Adocia has successfully formed partnerships with other companies in the industry to develop innovative therapies together. The company has also entered into a number of licensing agreements to use the intellectual property of others and improve its own processes and technologies. Overall, Adocia's business model is focused on researching and developing novel therapies for diabetes, autoimmune diseases, and cancer. The company has an impressive product pipeline and a strong funding base that allows it to continue its innovative research efforts. Adocia is a pioneer in the biopharmaceutical industry and is expected to continue to play a crucial role in improving the health of millions of patients worldwide.

Adocia maksab dividendi 0 EUR, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Adocia jaoks arvutada või ettevõte ei maksa dividende välja.

Adocia ISIN on FR0011184241.

Adocia WKN on A1JTC2.

Adocia tähis on ADOC.PA.

Viimase 12 kuu jooksul maksis Adocia dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Adocia tõenäoliselt dividendi summas 0 EUR.

Adocia praegune dividenditootlus on .

Adocia maksab kvartaalset dividendi. See makstakse välja kuudel .

Adocia maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 EUR. See vastab dividenditootlusele 0 %.

Adocia on liigitatud sektorisse 'Tervis'.

Viimase Adocia dividendide saamiseks 16.9.2024 suuruses 0 EUR pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 16.9.2024.

Viimane dividendimakse toimus 16.9.2024.

Aastal 2023 maksis Adocia 0 EUR dividende.

Adocia dividendid makstakse välja EUR.